7390 Results (Page 295 of 296)
Pharmaceuticals Markets Research Reports
US Congestive Heart Failure Therapeutics Market Analysis
The US Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $4.326 Bn in 2022 to $5.830 Bn by 2030, with a CAGR of 3.8% during the forecast period of 2022-2030. The key drivers of the market in the US include the increasing prevalence of risk factors, alongside rising investments in healthcare and growing initiatives for patient education and awareness, collectively fueling market expansion. The US Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi, etc., among various others.
UK Exosome Research Market Analysis
The UK Exosome Research Market was valued at $4.4 Mn in 2023 and is projected to grow at a CAGR of 14% from 2023 to 2023, to $11 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, increasing advanced applications of exosomes. The industry is primarily dominated by players such as AMS Biotechnology, Evox Therapeutics, Thermo Fisher Scientific among others.
Singapore Cardiac Resynchronization Therapy Market
Singapore Cardiac Resynchronization Therapy Market valued at $6 Mn in 2022, projected to reach $9 Mn by 2030 with a 5.6% CAGR. The notable increase in heart failure cases worldwide, propelled by aging demographics and lifestyle-associated cardiovascular ailments, stands as a pivotal factor fuelling the growth of the Cardiac Resynchronization Therapy (CRT) market. Presently, key players in this market encompass Abbott, Biotronik, Boston Scientific, Medtronic, St. Jude Medical, Sorin Group, Siemens Healthineers, Philips Healthcare, GE Healthcare, and Esaote.
US Exosome Research Market Analysis
The US Exosome Research Market was valued at $71 Mn in 2023 and is projected to grow at a CAGR of 14% from 2023 to 2023, to $177.6 Mn by 2030. The key drivers of this industry are increasing prevalence and incidences of cancer and various auto-immune diseases, rising healthcare expenditure for better health services, growing R&D activities associated with exosome research, technological advancements in exosome isolation and analytical procedures, and increasing advanced applications of exosomes. The industry is primarily dominated by players such as Thermo Fisher Scientific, NanoSomix, NX Pharmagen, Malvern Instruments, Capricor Therapeutics among others.
Saudi Arabia Cardiac Resynchronization Therapy Market
Saudi Arabia Cardiac Resynchronization Therapy Market valued at $82 Mn in 2022, projected to reach $135 Mn by 2030 with a 6.5% CAGR. The increasing worldwide incidence of heart failure, propelled by aging demographics and cardiovascular diseases linked to lifestyle, emerges as a significant factor fuelling the growth of the Cardiac Resynchronization Therapy (CRT) market. Presently, prominent players in this market encompass Medtronic, Abbott, Boston Scientific, Johnson & Johnson, Biotronik, St. Jude Medical, LivaNova, MicroPort, Sorin Group, and Siemens Healthineers.
Mexico Cardiac Resynchronization Therapy Market
Mexico Cardiac Resynchronization Therapy Market valued at $72 Mn in 2022, projected to reach $108 Mn by 2030 with a 5.25% CAGR. The global rise in heart failure cases, driven by aging populations and lifestyle-related cardiovascular diseases, is a key factor contributing to the expansion of the Cardiac Resynchronization Therapy (CRT) market. Currently, leading participants in this market include Abbott, Boston Scientific, Medtronic, Siemens Healthineers, Johnson & Johnson, Biotronik, LivaNova, MicroPort, Sorin Group, and St. Jude Medical.
Malaysia Cardiac Resynchronization Therapy Market
Malaysia Cardiac Resynchronization Therapy Market valued at $8 Mn in 2022, projected to reach $12 Mn by 2030 with a 5.2% CAGR. The notable increase in heart failure cases worldwide, propelled by aging demographics and lifestyle-associated cardiovascular ailments, stands as a pivotal factor fuelling the growth of the Cardiac Resynchronization Therapy (CRT) market. Presently, key players in this market encompass Abbott, Biotronik, Boston Scientific, Medtronic, Nihon Kohden, Oscor, Siemens Healthineers, Sorin Group, MicroPort CRM, and Osram Health.
Japan Cardiac Resynchronization Therapy Market
Japan Cardiac Resynchronization Therapy Market valued at $298 Mn in 2022, projected to reach $458 Mn by 2030 with a 5.5% CAGR. The global surge in heart failure cases, driven by aging populations and lifestyle-related cardiovascular diseases, is a significant catalyst contributing to the expansion of the Cardiac Resynchronization Therapy (CRT) market. Currently, major contributors to this market include companies such as Abbott, Biotronik, Boston Scientific, Medtronic, Nihon Kohden, Oscor, Siemens Healthineers, Sorin Group, MicroPort CRM, and Osram Health.
Kenya Cardiac Resynchronization Therapy Market
Kenya Cardiac Resynchronization Therapy Market valued at $3 Mn in 2022, projected to reach $5 Mn by 2030 with a 6.1% CAGR. The significant rise in global heart failure instances, driven by aging populations and cardiovascular conditions linked to lifestyle, emerges as a crucial catalyst propelling the expansion of the Cardiac Resynchronization Therapy (CRT) market. Currently, major participants in this market include Abbott, Biotronik, Boston Scientific, Medtronic, St. Jude Medical, Sorin Group, Siemens Healthineers, Philips Healthcare, GE Healthcare, and Esaote.
Germany Cardiac Resynchronization Therapy Market
Germany Cardiac Resynchronization Therapy Market valued at $176 Mn in 2022, projected to reach $226 Mn by 2030 with a 3.2% CAGR. The global rise in heart failure cases, driven by aging populations and lifestyle-related cardiovascular diseases, is a key factor contributing to the expansion of the Cardiac Resynchronization Therapy (CRT) market. Currently, leading participants in this market include Abbott, Boston Scientific, Medtronic, Biotronik, Siemens Healthineers, St. Jude Medical, Sorin Group, Edwards Lifesciences, LivaNova, and Terumo.
Canada Cardiac Resynchronization Therapy Market
Canada Cardiac Resynchronization Therapy Market valued at $384 Mn in 2022, projected to reach $567 Mn by 2030 with a 5% CAGR. The rising global prevalence of heart failure, driven by aging populations and lifestyle-related cardiovascular diseases, serves as a key growth driver for the Cardiac Resynchronization Therapy (CRT) market. Currently, leading pharmaceutical companies in this market include Abbott, Biotronik, Boston Scientific, Medtronic, St. Jude Medical, Sorin Group, Siemens Healthineers, Philips Healthcare, GE Healthcare, and Esaote.
Egypt Cardiac Resynchronization Therapy Market
Egypt Cardiac Resynchronization Therapy Market valued at $13 Mn in 2022, projected to reach $22 Mn by 2030 with a 6.5% CAGR. The significant rise in global heart failure instances, driven by aging populations and cardiovascular conditions linked to lifestyle, emerges as a crucial catalyst propelling the expansion of the Cardiac Resynchronization Therapy (CRT) market. Currently, major participants in this market include Abbott, Biotronik, Boston Scientific, Medtronic, St. Jude Medical, Sorin Group, Siemens Healthineers, Philips Healthcare, GE Healthcare, and Esaote.
Brazil Cardiac Resynchronization Therapy Market
Brazil Cardiac Resynchronization Therapy Market valued at $120 Mn in 2022, projected to reach $191 Mn by 2030 with a 6% CAGR. The global rise in heart failure cases, driven by aging populations and lifestyle-related cardiovascular diseases, is a key factor contributing to the expansion of the Cardiac Resynchronization Therapy (CRT) market. Currently, leading participants in this market include Abbott, Boston Scientific, Medtronic, Siemens Healthineers, Johnson & Johnson, Biotronik, LivaNova, MicroPort, Sorin Group, and St. Jude Medical.
China Cardiac Resynchronization Therapy Market
China Cardiac Resynchronization Therapy Market was valued at $386 Mn in 2022 and is estimated to reach $639 Mn in 2030, exhibiting a CAGR of 6.5% during the forecast period. The global surge in heart failure cases, driven by aging populations and lifestyle-related cardiovascular diseases, is a significant catalyst contributing to the expansion of the Cardiac Resynchronization Therapy (CRT) market. Currently, major contributors to this market include companies such as Medtronic, Boston Scientific, Abbott, Siemens Healthineers, MicroPort Apsara, Lepu Medical Technology Co., Beijing Easywell Medical Device Co., Shenzhen Lepu Heart Valve Technology Co., Terumo Corporation, and Osram Health.
South Africa Cancer Induced Bone Diseases Therapeutics Market
South Africa Cancer Induced Bone Diseases Therapeutics Market valued at $8 Mn in 2022, projected to reach $15 Mn by 2030 with a 7.03% CAGR. The key drivers of this industry include the rising burden of cancer, increased healthcare spending, and technological advancements in the therapeutics industry. The industry is primarily dominated by players such as Fresenius, AstraZeneca, Merck, Eli Lilly, Johnson & Johnson, Amgen, and Novartis among others.
Kenya Cancer Induced Bone Diseases Therapeutics Market
Kenya Cancer Induced Bone Diseases Therapeutics Market valued at $1 Mn in 2022, projected to reach $2 Mn by 2030 with a 6.9% CAGR. The key drivers of this industry include the rising incidence of cancer, the demographic shift to an aging population, and supportive government initiatives. The industry is primarily dominated by players such as Avenue Healthcare, AstraZeneca, Merck, Eli Lilly, Johnson & Johnson, Amgen, and Novartis among others.
Philippines Cardiac Arrhythmia Therapeutics Market
Philippines Cardiac Arrhythmia Therapeutics Market valued at $16 Mn in 2022, projected to reach $26 Mn by 2030 with a 6.3% CAGR. The key drivers of this industry include rising incidence of cardiac arrhythmias, increased healthcare spending, and technological advances. The industry is primarily dominated by players such as Abbott, Philips Healthcare, Boston Scientific, United Laboratories, Siemens, and Zuellig among others.
Kenya Cardiac Arrhythmia Therapeutics Market
Kenya Cardiac Arrhythmia Therapeutics Market valued at $5 Mn in 2022, projected to reach $9 Mn by 2030 with a 6.9% CAGR. The key drivers of this industry include the rising prevalence of cardiovascular diseases, expanding healthcare infrastructure, and evolving treatment landscape. The industry is primarily dominated by players such as Abbott, Pfizer, Metropolis, Mediheal, Chemicare, Johnson & Johnson, and Medtronic among others.
Indonesia Cardiac Arrhythmia Therapeutics Market
Indonesia Cardiac Arrhythmia Therapeutics Market valued at $43 Mn in 2022, projected to reach $68 Mn by 2030 with a 5.8% CAGR. The key drivers of this industry include a surge in the prevalence of cardiac arrhythmias, expanding healthcare access, and an evolving treatment landscape. The industry is primarily dominated by players such as Abbott, Philips, GE Healthcare, Boston Scientific, Stryker, Biotronik, and Esaote among others.
Japan Cardiac Arrhythmia Therapeutics Market
Japan Cardiac Arrhythmia Therapeutics Market valued at $448 Mn in 2022, projected to reach $730 Mn by 2030 with a 6.3% CAGR. The key drivers of this industry include the rising prevalence of cardiac arrhythmias, supportive government initiatives, and technological advancements. The industry is primarily dominated by players such as Abbott, Philips Healthcare, Boston Scientific, Olympus, Terumo, and Esaote among others.
France Cardiac Arrhythmia Therapeutics Market
France Cardiac Arrhythmia Therapeutics Market valued at $198 Mn in 2022, projected to reach $288 Mn by 2030 with a 4.8% CAGR. The key drivers of this industry include the increasing prevalence of cardiac conditions, technological advancements, and the emerging therapeutics landscape. The industry is primarily dominated by players such as Abbott, Medtronic, Biotronik, Philips, GE, Nuubo, and Boston Scientific among others.
Canada Cardiac Arrhythmia Therapeutics Market
Canada Cardiac Arrhythmia Therapeutics Market valued at $576 Mn in 2022, projected to reach $904 Mn by 2030 with a 5.8% CAGR. The key drivers of this industry include the rising prevalence of CVDs, technological advancements, and supportive government initiatives. The industry is primarily dominated by players such as Abbott, Medtronic, GE, Pfizer, Johnson & Johnson, Siemens, and Biosense Webster among others.
China Cardiac Arrhythmia Therapeutics Market
China Cardiac Arrhythmia Therapeutics Market valued at $579 Mn in 2022, projected to reach $1,017 Mn by 2030 with a 7.3% CAGR. The key drivers of this industry include a surge in the prevalence of cardiac arrhythmias, government initiatives, and technological advancements. The industry is primarily dominated by players such as Abbott, MicroPort, Lepu Medical Technologies, Boston Scientific, Terumo, and Merck among others.
Egypt Cardiac Arrhythmia Therapeutics Market
Egypt Cardiac Arrhythmia Therapeutics Market valued at $20 Mn in 2022, projected to reach $35 Mn by 2030 with a 7.3% CAGR. The key drivers of this industry include the increasing prevalence of cardiac arrhythmias, government initiatives, and technological advances. The industry is primarily dominated by players such as Abbott, Hikma, EPharm, Pharco, Sanofi, Boehringer Ingelheim, and AstraZeneca among others.
Brazil Cardiac Arrhythmia Therapeutics Market
Brazil Cardiac Arrhythmia Therapeutics Market valued at $180 Mn in 2022, projected to reach $305 Mn by 2030 with a 6.8% CAGR. The key drivers of this industry include the rising burden of cardiac conditions, technological advancements, and growing healthcare expenditure. The industry is primarily dominated by players such as Abbott, Medtronic, Biotronik, Biolab Sanus, Johnson & Johnson, and Boston Scientific among others.